Press release
September 17, 2026
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
Tiziana Life Sciences Ltd (TLSA)
BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody,